Literature DB >> 26309561

Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction.

Xiaowei Dang1, Luhao Li1, Suxin Li1, Yafei Wang1, Hai Li1, Shaokai Xu1, Peiqin Xu1.   

Abstract

BACKGROUND: To investigate the characteristics of Budd-Chiari syndrome (B-CS) types, rate of HCC complicated by different types of B-CS and values of CTA in diagnosis of B-CS and HCC complicated by B-CS.
MATERIAL AND METHODS: 494 patients with B-CS were analyzed retrospectively. All patients underwent CTA, which was used to assess the accuracy of diagnosing B-CS and the rate of HCC complicated by various kinds of B-CS. Digital subtraction angiography (DSA) and pathological examination were used as gold standard.
RESULTS: Among 494 patients diagnosed by DSA, there were 21 (4.3%) cases of inferior vena cava type, 80 (16.2%) cases of hepatic vein type and 393 (79.6%) cases of hepatic vein combined with inferior vena cava complex type. The accuracy of diagnosing B-CS by CTA was 86.6% (428/494), in which the accuracy of diagnosing inferior vena cava type was 85.7% (18/21), 83.8% (67/80) for hepatic vein type and 87.3% (343/393) for complex type. The rate of HCC complicated by B-CS was 12.8% (63/494), among which inferior vena cava type was 4.8% (1/21), hepatic vein type was 11.3% (9/80) and complex type was 13.5% (53/393). There were no statistic differences between these three types (P=0.459). The accuracy of diagnosing HCC by CTA was 82.5% (52/63).
CONCLUSION: B-CS in patients from China's Yellow River basin is mainly hepatic vein combined with inferior vena cava complex type, which is more likely to be complicated by HCC. CTA plays an important role in diagnosing B-CS and HCC complicated by B-CS.

Entities:  

Keywords:  Budd-chiari syndrome; computed tomographic angiography; hepatocellular carcinoma; incidence

Year:  2015        PMID: 26309561      PMCID: PMC4537987     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  28 in total

1.  Budd-Chiari syndrome and hepatocellular carcinoma.

Authors:  Masayoshi Kage
Journal:  J Gastroenterol       Date:  2004-07       Impact factor: 7.527

2.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

3.  [Comparison of collateral circulation characteristics between Budd-Chiari syndrome and hepatitis B related liver cirrhosis with CT angiography].

Authors:  Jin Peng; Xiaodong Wang; Weixia Chen; Dongsheng Wu; Acharya Riwaz; Zhenlin Li
Journal:  Sheng Wu Yi Xue Gong Cheng Xue Za Zhi       Date:  2013-10

4.  Surgical treatment of Budd-Chiari syndrome: analysis of 221 cases.

Authors:  Xiao-Wei Dang; Pei-Qin Xu; Xiu-Xian Ma; Da-Qian Xu; Yan-Ju Zhu; Yong-Shuai Zhang
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2011-08

5.  Benign hepatic nodules in Budd-Chiari syndrome: radiologic-pathologic correlation with emphasis on the central scar.

Authors:  Yoji Maetani; Kyo Itoh; Hiroto Egawa; Hironori Haga; Takaki Sakurai; Naoshi Nishida; Fumie Ametani; Toshiya Shibata; Takeshi Kubo; Koichi Tanaka; Junji Konishi
Journal:  AJR Am J Roentgenol       Date:  2002-04       Impact factor: 3.959

6.  Rapid development of a hepatocellular carcinoma in isolated thrombosis of hepatic veins (classic Budd-Chiari syndrome): case report and review of literature.

Authors:  Jens Walldorf; Andrea Tannapfel; Hans Jürgen Holzhausen; Christian Wittekind; Thomas Seufferlein; Utz Settmacher; Wolfgang E Fleig; Matthias M Dollinger
Journal:  BMJ Case Rep       Date:  2009-11-29

Review 7.  Spiral computed tomography and magnetic resonance angiography evaluation in Budd-Chiari syndrome.

Authors:  Ioana Gabriela Lupescu; Cristina Dobromir; Gelu A Popa; Liana Gheorghe; Serban A Georgescu
Journal:  J Gastrointestin Liver Dis       Date:  2008-06       Impact factor: 2.008

8.  Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE.

Authors:  Dong Gwon; Gi-Young Ko; Hyun-Ki Yoon; Kyu-Bo Sung; Jin Hyoung Kim; Seung Soo Lee; Jae Myeong Lee; Joon-Young Ohm; Ji Hoon Shin; Ho-Young Song
Journal:  Radiology       Date:  2010-02       Impact factor: 11.105

9.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

10.  Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization.

Authors:  Feng-Yong Liu; Mao-Qiang Wang; Feng Duan; Qing-Sheng Fan; Peng Song; Yan Wang
Journal:  BMC Gastroenterol       Date:  2013-06-24       Impact factor: 3.067

View more
  2 in total

1.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

2.  Liver cirrhosis caused by chronic Budd-Chiari syndrome.

Authors:  Mengjie Lin; Feng Zhang; Yi Wang; Bin Zhang; Wei Zhang; Xiaoping Zou; Ming Zhang; Yuzheng Zhuge
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.